Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

7
E*TRADE (ETFC) Tops Q2 Estimates

4h zacks
E*TRADE Financial (ETFC - Free Report) just released its second quarter financial results, posting adjusted earnings of $0.95 per share and revenues of $710 million.
WFC WFCNP HON WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO HON ETFC WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

4
Options Traders Expect Huge Moves in E*TRADE (ETFC) Stock

13h zacks
Investors in E*TRADE Financial Corporation (ETFC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $52 Put had some of the highest implied volatility of all equity options today.
ETFC NBRV EIGR NCS

18
Should You Buy E*TRADE (ETFC) Ahead of Earnings?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season E*TRADE Financial Corporation (ETFC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL JAKK FTRPR ETFC FTR

16
Interactive Brokers (IBKR) Beats on Q2 Earnings, Costs Down

2018-07-18 zacks
Interactive Brokers Group, Inc. (IBKR - Free Report) released second-quarter 2018 results. Earnings per share of 58 cents surpassed the Zacks Consensus Estimate of 51 cents. Also, the figure was higher than prior-year quarter’s earnings of 32 cents per share. Results benefited from an improvement in revenues and rise in DARTs along with lower expenses. Further, the Electronic Brokerage segment continued to perform decently.
LPLA GEC GE ETFC IBKR AMTD GNE

18
Will Loan Growth, Fee Income Aid SunTrust (STI) Q2 Earnings?

2018-07-18 zacks
SunTrust Banks (STI - Free Report) is scheduled to report second-quarter 2018 results on Jul 20, before the opening bell. Its revenues and earnings are projected to grow year over year. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from rise in net interest income as well as lower expenses and provisions. However, a decline in non-interest income was the undermining factor.
STT STI.WS.B GEC GE STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG KEY STI ETFC STI-A GNE STI.PRE

3
Can Higher Rates Aid State Street's (STT) Earnings in Q2?

2018-07-18 zacks
State Street (STT - Free Report) is scheduled to report second-quarter 2018 results on Jul 20, before the market opens. Its earnings and revenues are expected to grow year over year. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results were aided by an increase in revenues, partly offset by higher expenses. Moreover, State Street boasts an impressive earnings surprise history.
STT HD STI.WS.B STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG KEY STI ETFC STI-A STI.PRE

2
Why is Earnings Beat Less Likely for BNY Mellon (BK) in Q2?

2018-07-17 zacks
The Bank of New York Mellon Corporation (BK - Free Report) is scheduled to report second-quarter 2018 results on Jul 19, before the market opens. Its revenues and earnings are expected to grow year over year. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Higher revenues and assets under management (AUM) growth were partially offset by rise in expenses.
HD STI.WS.B STI.WS.A STI BK ETFC STI-A STI.PRE KEY

1
Schwab (SCHW) Beats Q2 Earnings on Higher Interest Income

2018-07-17 zacks
Charles Schwab’s (SCHW - Free Report) second-quarter 2018 earnings of 60 cents per share surpassed the Zacks Consensus Estimate of 58 cents. Also, earnings surged 54% from the prior-year quarter. Schwab’s shares were up nearly 2.5% in pre-market trading. Notably, price reaction during the full trading session will provide a better idea about how investors accepted the results. Revenue growth (driven by a rise in interest income and trading revenues) and absence of fee waivers supported the results.
SCHW.PRBCL ETFC AMTD RJD RJF

2
Can Loan Growth, Higher Rates Aid KeyCorp (KEY) Q2 Earnings?

2018-07-17 zacks
KeyCorp (KEY - Free Report) is slated to announce second-quarter 2018 results on Jul 19, before the opening bell. The company is expected to show some improvement in net interest income (NII), driven by higher interest rates, while the flattening of the yield curve is likely to hamper growth to some extent. While the overall loan growth in the second quarter was not impressive, commercial and industrial loans witnessed modest growth.
STI.WS.B STI.WS.A STI ETFC STI-A STI.PRE KEY

2
Is an Earnings Beat in Store for Blackstone (BX) in Q2?

2018-07-17 zacks
The Blackstone Group L.P. (BX - Free Report) is scheduled to report second-quarter 2018 results on Jul 19, before the opening bell. Its revenues and earnings are projected to grow on a year-over-year basis. In the last reported quarter, the company’s economic net income surpassed the Zacks Consensus Estimate. Growth in assets under management (AUM) was partially offset by a decline in revenues and higher expenses.
STI.WS.B STI.WS.A STI ETFC STI-A VEEV STI.PRE KEY SGH

2
E*TRADE (ETFC) to Report Q2 Earnings: Is a Beat in Store?

2018-07-17 zacks
E*TRADE Financial Corporation (ETFC - Free Report) is scheduled to report second-quarter 2018 results on Jul 19. The company is expected to witness year-over-year growth in revenues and earnings.
STI.WS.B STI.WS.A STI ETFC STI-A VEEV STI.PRE KEY SGH

4
Is E*TRADE Financial (ETFC) Outperforming Other Finance Stocks This Year?

2018-07-16 zacks
Investors focused on the Finance space have likely heard of E*TRADE Financial (ETFC - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Finance sector should help us answer this question.
GTT ETFC

5
What's in Store for PNC Financial (PNC) in Q2 Earnings?

2018-07-12 zacks
The PNC Financial Services Group (PNC - Free Report) is scheduled to report second-quarter 2018 results on Jul 13, before the opening bell. Its revenues and earnings are projected to grow year over year. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from an improvement in net interest income as well as non-interest income, partially offset by higher expenses.
LMT CMA.WS CMA PNC.PRP PNC.PRQ PNCFO CMPWW PNC.WS 7018 CME ETFC PNC PNUCL

0
ETFC / E*TRADE Financial, Inc. S-8

2018-06-29 sec.gov
S-8 As filed with the U.S. Securities and Exchange Commission on June 29, 2018 Registration Statement No. 333-
ETFC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ETFC / E*TRADE Financial, Inc. on message board site Silicon Investor.

ET and the Rest E*Trade
ICSI,ETFC,RWIG,CPZR,SEBT,GDMN, MTMH Another Big Scam? ETFC Buy Back Program
CUSIP: 269246401